These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 28325713)
21. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint. Baker SG Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889 [TBL] [Abstract][Full Text] [Related]
23. Publication Speed, Reporting Metrics, and Citation Impact of Cardiovascular Trials Supported by the National Heart, Lung, and Blood Institute. Gordon D; Cooper-Arnold K; Lauer M J Am Heart Assoc; 2015 Jul; 4(8):e002292. PubMed ID: 26231845 [TBL] [Abstract][Full Text] [Related]
24. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Bakal JA; Westerhout CM; Armstrong PW Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378 [TBL] [Abstract][Full Text] [Related]
25. Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma. Medeiros FA Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO20-BIO26. PubMed ID: 28475699 [TBL] [Abstract][Full Text] [Related]
26. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Raghu G; Collard HR; Anstrom KJ; Flaherty KR; Fleming TR; King TE; Martinez FJ; Brown KK Am J Respir Crit Care Med; 2012 May; 185(10):1044-8. PubMed ID: 22505745 [TBL] [Abstract][Full Text] [Related]
27. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. Phillips PP; Fielding K; Nunn AJ PLoS One; 2013; 8(5):e63840. PubMed ID: 23667677 [TBL] [Abstract][Full Text] [Related]
29. Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time. Baker SG; Sargent DJ; Buyse M; Burzykowski T Biometrics; 2012 Mar; 68(1):248-57. PubMed ID: 21838732 [TBL] [Abstract][Full Text] [Related]
30. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941 [TBL] [Abstract][Full Text] [Related]
31. Predictors as well as surrogate and hard endpoints in cardiovascular disease. Lüscher TF Eur Heart J; 2015 Sep; 36(33):2197-9. PubMed ID: 26330463 [No Abstract] [Full Text] [Related]
32. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial. Tanaka S; Matsuyama Y; Ohashi Y Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043 [TBL] [Abstract][Full Text] [Related]
33. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. Bikdeli B; Welsh JW; Akram Y; Punnanithinont N; Lee I; Desai NR; Kaul S; Stone GW; Ross JS; Krumholz HM Circulation; 2019 Jul; 140(5):379-389. PubMed ID: 31177811 [TBL] [Abstract][Full Text] [Related]
34. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678 [TBL] [Abstract][Full Text] [Related]
35. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. Sofeu CL; Emura T; Rondeau V Stat Med; 2019 Jul; 38(16):2928-2942. PubMed ID: 30997685 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers and surrogate endpoints in clinical trials. Fleming TR; Powers JH Stat Med; 2012 Nov; 31(25):2973-84. PubMed ID: 22711298 [TBL] [Abstract][Full Text] [Related]
39. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Kastelein JJ; de Groot E Eur Heart J; 2008 Apr; 29(7):849-58. PubMed ID: 18334471 [TBL] [Abstract][Full Text] [Related]
40. Surrogate endpoints for overall survival in lung cancer trials: a review. Fiteni F; Westeel V; Bonnetain F Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]